Cargando…

A Glucagon-Like Peptide-1 Receptor Agonist Lowers Weight by Modulating the Structure of Gut Microbiota

In addition to improving glucose metabolism, liraglutide, a glucagon-like peptide-1 receptor agonist, has weight-loss effects. The underlying mechanisms are not completely understood. This study was performed to explore whether liraglutide could lower weight by modulating the composition of the gut...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhao, Li, Chen, Yi, Xia, Fangzhen, Abudukerimu, Buatikamu, Zhang, Wen, Guo, Yuyu, Wang, Ningjian, Lu, Yingli
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2018
Materias:	Endocrinology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5966539/ https://www.ncbi.nlm.nih.gov/pubmed/29867765 http://dx.doi.org/10.3389/fendo.2018.00233

Ejemplares similares

Effect of dual glucose-dependent insulinotropic peptide/glucagon-like peptide-1 receptor agonist on weight loss in subjects with obesity
por: Zaffina, Isabella, et al.
Publicado: (2023)

It Is Time to Consider Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Type 2 Diabetes in Youth
por: Oberle, Megan M., et al.
Publicado: (2019)

Utilization of glucagon-like peptide-1 receptor agonists in children and adolescents in China: a real-world study
por: Yan, Yilong, et al.
Publicado: (2023)

Berberine Slows the Progression of Prediabetes to Diabetes in Zucker Diabetic Fatty Rats by Enhancing Intestinal Secretion of Glucagon-Like Peptide-2 and Improving the Gut Microbiota
por: Wang, Ying, et al.
Publicado: (2021)

LH/FSH Ratio Is Associated With Visceral Adipose Dysfunction in Chinese Women Older Than 55
por: Zhao, Li, et al.
Publicado: (2018)

Role of Glucagon-Like Peptide-1 Receptor Agonists on the Weight Loss of Individuals With Type 2 Diabetes: A Systematic Review
por: Irfan, Huma, et al.
Publicado: (2023)

Dissecting the Physiology and Pathophysiology of Glucagon-Like Peptide-1
por: Paternoster, Silvano, et al.
Publicado: (2018)

A Combination of Glucagon-Like Peptide-1 Receptor Agonist and Dietary Intervention Could Be a Promising Approach for Obesity Treatment
por: Lee, Chooi Yeng
Publicado: (2021)

Comparison of the Efficacy of Glucagon-Like Peptide-1 Receptor Agonists in Patients With Metabolic Associated Fatty Liver Disease: Updated Systematic Review and Meta-Analysis
por: Dai, Yuzhao, et al.
Publicado: (2021)

Glucagon‐like peptide‐1 receptor agonists and their effects on weight reduction
por: Shin, Shyi‐Jang
Publicado: (2012)

Glucagon-Like Peptide-1 Receptor Agonists for Chronic Weight Management
por: Wojtara, Magda, et al.
Publicado: (2023)

Comparison of the Prevalence of Metabolic Disease Between Two Types of Urbanization in China
por: Han, Bing, et al.
Publicado: (2018)

The Associations Between Gonadal Hormones and Serum Uric Acid Levels in Men and Postmenopausal Women With Diabetes
por: Wan, Heng, et al.
Publicado: (2020)

Glucagon‐like peptide‐1 receptor agonist regulates fat browning by altering the gut microbiota and ceramide metabolism
por: Lin, Ke, et al.
Publicado: (2023)

Glucagon-Like Peptide-1 Receptor Agonists for Non-Alcoholic Fatty Liver Disease in Type 2 Diabetes: A Meta-Analysis
por: Wong, Chloe, et al.
Publicado: (2021)

MON-226 FSH Promotes Renal Tubulointerstitial Fibrosis Via AKT/GSK-3beta/beta-catenin Pathway
por: Zhang, Kun, et al.
Publicado: (2019)

GRK Inhibition Potentiates Glucagon-Like Peptide-1 Action
por: Lee, Seunghun P., et al.
Publicado: (2021)

Weight Loss of Over 100 lbs in a Patient of Prader-Willi Syndrome Treated With Glucagon-Like Peptide-1 (GLP-1) Agonists
por: Ahmed, Sana, et al.
Publicado: (2023)

Regulation of glucagon‐like peptide‐1 sensitivity by gut microbiota dysbiosis
por: Yamane, Shunsuke, et al.
Publicado: (2017)

Can glucagon-like peptide-1 receptor agonists cause acute kidney injury? An analytical study based on post-marketing approval pharmacovigilance data
por: Dong, Shichao, et al.
Publicado: (2022)

Comparison of the efficacy and safety of 10 glucagon-like peptide-1 receptor agonists as add-on to metformin in patients with type 2 diabetes: a systematic review
por: Xie, Zeyu, et al.
Publicado: (2023)

Modulation of Microbiota-Gut-Brain Axis by Berberine Resulting in Improved Metabolic Status in High-Fat Diet-Fed Rats
por: Sun, Honglin, et al.
Publicado: (2017)

Glucagon‐like peptide‐1 receptor agonists, weight loss, and gastric emptying: have I gut news for you
por: Jalleh, Ryan J., et al.
Publicado: (2022)

Effects of Sodium-Glucose Cotransporter Inhibitor/Glucagon-Like Peptide-1 Receptor Agonist Add-On to Insulin Therapy on Glucose Homeostasis and Body Weight in Patients With Type 1 Diabetes: A Network Meta-Analysis
por: Kim, Yoon Ji, et al.
Publicado: (2020)

Association of glucagon‐like peptide‐1 receptor‐targeted imaging probe with in vivo glucagon‐like peptide‐1 receptor agonist glucose‐lowering effects
por: Murakami, Takaaki, et al.
Publicado: (2020)

SUN-236 Testosterone and Glucagon-Like Peptide-1 Agonists for Type 2 Diabetes Mellitus: A Prospective Cohort Study
por: Graybill, Sky
Publicado: (2019)

Bone Turnover Markers and Probable Advanced Nonalcoholic Fatty Liver Disease in Middle-Aged and Elderly Men and Postmenopausal Women With Type 2 Diabetes
por: Wang, Ningjian, et al.
Publicado: (2020)

Cardiovascular and renal burdens among patients with MAFLD and NAFLD in China
por: Wang, Yuying, et al.
Publicado: (2022)

Ghrelin Is a Regulator of Glucagon-Like Peptide 1 Secretion and Transcription in Mice
por: Lindqvist, Andreas, et al.
Publicado: (2017)

The Impact of Glucagon-Like Peptide-1 on Bone Metabolism and Its Possible Mechanisms
por: Zhao, Chenhe, et al.
Publicado: (2017)

Real-world national trends and socio-economic factors preference of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists in China
por: Li, Cao, et al.
Publicado: (2022)

Weight loss with glucagon‐like peptide‐1 receptor agonists in Bardet‐Biedl syndrome
por: Ganawa, Shawg, et al.
Publicado: (2022)

Intestinal Sensing by Gut Microbiota: Targeting Gut Peptides
por: Covasa, Mihai, et al.
Publicado: (2019)

Glucagon-like peptide-1 and glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes
por: Lee, Seungah, et al.
Publicado: (2017)

SAT-570 Should Severe Hypertriglyceridemia Also Be Considered as a Contraindication for Use of Glucagon like Peptide 1 (GLP-1) Agonists?
por: Guzman, Amelia
Publicado: (2020)

OR21-1 Adiposity and Diabetes Genetic Risk Modulates Causal Effects of BMI and Type 2 Diabetes on NAFLD: A Wax-and-Wane Pattern
por: Wang, Ningjian, et al.
Publicado: (2019)

Glucagon-like peptide-1 receptor overexpression in cancer and its impact on clinical applications
por: Körner, Meike, et al.
Publicado: (2012)

The Interplay of Glucagon-Like Peptide-1 Receptor Trafficking and Signalling in Pancreatic Beta Cells
por: Marzook, Amaara, et al.
Publicado: (2021)

Role of Glucagon-Like Peptide-1 Receptor Agonists in the Management of Non-Alcoholic Steatohepatitis: A Clinical Review Article
por: Ghazanfar, Haider, et al.
Publicado: (2021)

Resveratrol Modulates the Gut-Brain Axis: Focus on Glucagon-Like Peptide-1, 5-HT, and Gut Microbiota
por: Chung, Ji Yeon, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ko01d804hcf471ssjqpbb6l0o7